Teva reported a 2% decline and 9% growth in revenue and adjusted EPS, respectively, during the third fiscal quarter. Teva raised full-year revenue guidance by a low-single-digit percentage. Shares rose over 5% in early trading.
Portfolio improvements from continued uptick of commercial branded drugs and launch of pipeline assets should bolster Teva's top and bottom lines for the next decade.
The majority of Teva's business lies in generic and off-patent branded drugs, which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply chain exert force.
Metric | TEVA | VTRS | SDZ |
|---|---|---|---|
Price/Earnings (Normalized) | 16.37 | 15.56 | 49.75 |
Price/Book Value | 6.51 | 1.74 | 5.03 |
Price/Sales | 3.04 | 1.63 | 4.00 |
Price/Cash Flow | 17.11 | 8.96 | 41.15 |
Metric | TEVA | VTRS | SDZ |
|---|---|---|---|
Quick Ratio | 0.51 | 0.82 | 0.50 |
Current Ratio | 0.95 | 1.55 | 1.05 |
Interest Coverage | 1.42 | −0.11 | 4.66 |
Metric | TEVA | VTRS | SDZ |
|---|---|---|---|
Return on Assets (Normalized) | 6.94% | 8.21% | 7.69% |
Return on Equity (Normalized) | 35.60% | 20.56% | 18.79% |
Return on Invested Capital (Normalized) | 13.90% | 11.60% | 12.29% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|sMfpZgqf | LOCK|&TgL# | $72B | |||
| Haleon PLC ADR HLN | LOCK|#@#&$X | LOCK|Pz | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|!SGVmgGB | LOCK|V<Q | $34B | |||
| Viatris Inc VTRS | LOCK|RH?p@c | LOCK|FN | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|GM | LOCK|Wc# | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|g!#xqPq | LOCK|m% | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|Tg@%P@ | LOCK|L& | $5B | |||
| Perrigo Co PLC PRGO | LOCK|Hw$wtK | LOCK|>D | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|nG^%@? | LOCK|cL^?T | $2B |
United States